Clinical Trial Update: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC [Phase 2]

View source ↗

Summary

A Phase 2 trial update for QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment in unresectable advanced or metastatic colore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Colorectal Carcinoma | Phase 2 | Status: UNKNOWN